Gemcitabine in Bone Sarcoma Resistant to Doxorubicin‐BasedChemotherapy
Authors:
Open Access
Abstract
Subjects and Methods: Seven patients with progressive localized or metastatic chemo-resistant osteosarcoma were treated by gemcitabine.The protocol included gemcitabine 1000 mg/m2/w for 7 consecutive weeks, followed by 1 week rest. If no progression was observed,maintenance by gemcitabine 1000 mg/m2/w for 3 weeks every 28 days was given until failure was clinically or radiologically evident.Keywords
This publication has 10 references indexed in Scilit:
- Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II studyCancer Chemotherapy and Pharmacology, 2000
- Palliative effect of gemcitabine in osteosarcoma resistant to standard chemotherapy.1998
- A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancerAnnals of Oncology, 1996
- Phase II study of gemcitabine in patients with advanced pancreatic cancerBritish Journal of Cancer, 1996
- Schedule-dependent antitumor effect of gemcitabine in in vivo model system.1995
- Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study.Journal of Clinical Oncology, 1994
- The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancerBritish Journal of Cancer, 1993
- Treatment of unresectable or metastatic osteosarcoma with cisplatin or cisplatin–doxorubicinCancer, 1985
- Treatment of patients with metastatic osteogenic sarcoma: a report from the Children's Cancer Study Group.1984
- Chemotherapy for metastic osteosarcoma--studies by the M.D. Anderson Hospital and the Southwest Oncology Group.1978